Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry-Reference-Cited by-同舟云学术

Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry

Published:1998-04 Issue:1 Volume:101 Page:158-164
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:British Journal of Haematology

Author:

Farahat Nahla,Morilla Alison,Owusu-Ankomah Kwasi,Morilla Ricardo,Pinkerton C. Ross,Treleaven Jennie G.,Matutes Estella,Powles Ray L.,Catovsky Daniel

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.1998.00675.x/fullpdf

Reference31 articles.

1. Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group study;Abshire;Leukemia,1992

2. Flow cytometric determination of leukemia-associated marker combinations for the study of minimal residual disease;Babusikova;Neoplasma,1994

3. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations;Bennett;British Journal of Haematology,1981

4. Monitoring minimal residual disease in acute leukemia: expectations, possibilities and initial clinical results;Campana;International Journal of Clinical Laboratory Research,1994

5. The immunologic detection of minimal residual disease in acute leukemia;Campana;Blood,1990

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antigen Receptors Gene Analysis for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia: The Role of High Throughput Sequencing;Hemato;2023-01-09

2. Flow cytometric myeloma measurable residual disease testing in the era of targeted therapies;International Journal of Laboratory Hematology;2021-07

3. Comparing morphology, flow cytometry and molecular genetics in the assessment of minimal residual disease in children with B-acute lymphoblastic leukaemia (B-ALL);South African Journal of Oncology;2019-10-23

4. Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies;Human Vaccines & Immunotherapeutics;2018-11-20

5. Minimal Residual Disease Testing in Acute Lymphoblastic Leukemia/Lymphoma;Minimal Residual Disease Testing;2018-11-16